SNGX

Soligenix, Inc. (NASDAQ:SNGX) is a late-stage biopharmaceutical company founded in 1987 and headquartered in Princeton, New Jersey. Originally incorporated as DOR BioPharma, Inc., the company changed its name to Soligenix in 2009 and went public in 1994. The company focuses on developing and commercializing treatments for rare diseases and public health threats, operating through two distinct business segments that address both specialized medical conditions and broader public health challenges.